Jiangsu Hengrui Pharmaceuticals Co., Ltd.

This profile gathers the share dealings of Jiangsu Hengrui Pharmaceuticals Co., Ltd. across 2 companies, led by Kailera Therapeutics, Inc. and Braveheart Bio, Inc. The record holds 3 filings, for trades running from 20 April 2026 to 7 August 2026.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

The latest filing, published on 10 August 2026, reports a transaction in Braveheart Bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.